Quadcap Wealth Management LLC Lowers Holdings in Thermo Fisher Scientific Inc. $TMO

Quadcap Wealth Management LLC reduced its stake in shares of Thermo Fisher Scientific Inc. (NYSE:TMO) by 6.5% in the first quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund owned 2,033 shares of the medical research company’s stock after selling 142 shares during the quarter. Quadcap Wealth Management LLC’s holdings in Thermo Fisher Scientific were worth $1,012,000 as of its most recent SEC filing.

Other hedge funds have also recently made changes to their positions in the company. Bernard Wealth Management Corp. purchased a new stake in shares of Thermo Fisher Scientific during the 4th quarter worth $25,000. Ameriflex Group Inc. purchased a new stake in shares of Thermo Fisher Scientific during the 4th quarter worth $30,000. Keystone Global Partners LLC purchased a new stake in shares of Thermo Fisher Scientific during the 1st quarter worth $31,000. IMA Advisory Services Inc. purchased a new stake in shares of Thermo Fisher Scientific during the 1st quarter worth $35,000. Finally, Navigoe LLC purchased a new stake in shares of Thermo Fisher Scientific during the 4th quarter worth $37,000. 89.23% of the stock is currently owned by hedge funds and other institutional investors.

Insider Activity

In related news, EVP Gianluca Pettiti sold 400 shares of Thermo Fisher Scientific stock in a transaction that occurred on Friday, July 25th. The stock was sold at an average price of $479.98, for a total transaction of $191,992.00. Following the transaction, the executive vice president owned 22,367 shares in the company, valued at approximately $10,735,712.66. This trade represents a 1.76% decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which can be accessed through this link. Also, CEO Marc N. Casper sold 10,000 shares of Thermo Fisher Scientific stock in a transaction that occurred on Friday, August 22nd. The stock was sold at an average price of $500.96, for a total value of $5,009,600.00. Following the transaction, the chief executive officer owned 115,174 shares in the company, valued at approximately $57,697,567.04. The trade was a 7.99% decrease in their position. The disclosure for this sale can be found here. Over the last ninety days, insiders have sold 28,896 shares of company stock worth $13,603,438. 0.33% of the stock is owned by corporate insiders.

Analysts Set New Price Targets

TMO has been the topic of several recent analyst reports. HSBC reaffirmed a “hold” rating and set a $510.00 target price on shares of Thermo Fisher Scientific in a research report on Thursday, July 24th. Barclays upped their target price on Thermo Fisher Scientific from $450.00 to $490.00 and gave the company an “equal weight” rating in a research report on Thursday, July 24th. Wall Street Zen lowered Thermo Fisher Scientific from a “buy” rating to a “hold” rating in a research report on Sunday, August 10th. Argus reduced their target price on Thermo Fisher Scientific from $620.00 to $470.00 and set a “buy” rating on the stock in a research report on Tuesday, April 29th. Finally, William Blair initiated coverage on Thermo Fisher Scientific in a research report on Monday, August 18th. They set an “outperform” rating on the stock. Sixteen analysts have rated the stock with a Buy rating and six have given a Hold rating to the company. According to data from MarketBeat, the company presently has a consensus rating of “Moderate Buy” and an average price target of $593.00.

Thermo Fisher Scientific Price Performance

Shares of NYSE:TMO opened at $488.93 on Wednesday. Thermo Fisher Scientific Inc. has a twelve month low of $385.46 and a twelve month high of $627.88. The company’s 50 day moving average is $446.71 and its 200 day moving average is $455.47. The company has a current ratio of 1.93, a quick ratio of 1.50 and a debt-to-equity ratio of 0.65. The company has a market cap of $184.63 billion, a PE ratio of 28.28, a price-to-earnings-growth ratio of 2.62 and a beta of 0.74.

Thermo Fisher Scientific (NYSE:TMO) last posted its earnings results on Wednesday, July 23rd. The medical research company reported $5.36 EPS for the quarter, topping the consensus estimate of $5.22 by $0.14. The firm had revenue of $10.86 billion for the quarter, compared to analyst estimates of $10.68 billion. Thermo Fisher Scientific had a return on equity of 16.82% and a net margin of 15.24%.Thermo Fisher Scientific’s revenue for the quarter was up 2.9% compared to the same quarter last year. During the same period last year, the company earned $5.37 earnings per share. Thermo Fisher Scientific has set its Q3 2025 guidance at 5.460-5.510 EPS. FY 2025 guidance at 22.220-22.840 EPS. On average, sell-side analysts forecast that Thermo Fisher Scientific Inc. will post 23.28 EPS for the current year.

Thermo Fisher Scientific Dividend Announcement

The business also recently announced a quarterly dividend, which will be paid on Wednesday, October 15th. Investors of record on Monday, September 15th will be issued a dividend of $0.43 per share. This represents a $1.72 annualized dividend and a yield of 0.4%. The ex-dividend date of this dividend is Monday, September 15th. Thermo Fisher Scientific’s dividend payout ratio (DPR) is 9.95%.

About Thermo Fisher Scientific

Thermo Fisher Scientific Inc provides life sciences solutions, analytical instruments, specialty diagnostics, and laboratory products and biopharma services in the North America, Europe, Asia-Pacific, and internationally. The company's Life Sciences Solutions segment offers reagents, instruments, and consumables for biological and medical research, discovery, and production of drugs and vaccines, as well as diagnosis of infections and diseases; and solutions include biosciences, genetic sciences, and bio production to pharmaceutical, biotechnology, agricultural, clinical, healthcare, academic, and government markets.